Tracer
Tracer provides a software platform that decentralizes Minimal Residual Disease (MRD) testing by turning any high-throughput NGS sequencer or dPCR system into a tissue-free, single-ppm cancer detection tool. The vendor-agnostic solution converts raw data into quantitative Tumor Fraction reports, with results available in under 48 hours via secure cloud or same-day through on-premise deployment, enabling hospitals, CROs, and biopharma sites to become immediate MRD service providers.
- Healthcare Technology
- Digital Health
- Biotechnology
- Software Only
- Artificial Intelligence
Funding
Founders
Founder details are not available yet.
Product
Problem
Cancer relapse monitoring is constrained by centralized testing facilities, tissue biopsy limitations, and lengthy turnaround times that delay timely access to critical Minimal Residual Disease (MRD) insights. This logistical bottleneck prevents many patients from receiving the frequent, sensitive monitoring needed to detect recurrence early.
Solution
Tracer decentralizes MRD testing by providing a software platform that transforms any existing high-throughput NGS sequencer or dPCR system into a tissue-free, single-ppm cancer detection tool. The vendor-agnostic solution processes raw sequencing data into quantitative Tumor Fraction reports, eliminating the need for specialized hardware or proprietary reagents. Hospitals, CROs, and biopharma sites can stream FASTQs to Tracer's secure cloud for results in under 48 hours, or deploy the encrypted on-premise solution for same-day insights within their own network. This enables any participating site to become an immediate MRD service provider without significant capital investment or workflow disruption.
Target Audience
Primary customers are hospitals, Contract Research Organizations (CROs), and biopharma sites seeking to become immediate MRD testing service providers using their existing sequencing infrastructure.
Features
- Plug-and-play software integration with high-throughput NGS instruments (NovaSeq, Ultima, MGI) and commercial dPCR systems
- Vendor-agnostic design leveraging existing generic WGS or dPCR reagents to eliminate vendor lock-in and reduce costs
- Flexible deployment options: secure cloud for results in under 48 hours or encrypted on-premise for same-day insights
- WGS MRD offering with 10 ppm sensitivity tumor-naïve and 1 ppm tumor-informed, using comprehensive plasma whole-genome sequencing (30x-300x) with AI-powered signal extraction
- dPCR MRD offering featuring high-sensitivity patient-specific panels with 10-100 ppm sensitivity
- Tissue-free workflow requiring only a 10 mL plasma sample with standard cfDNA preparation